ecrin-mdr-crcClinical2017Cáncer colorectal avanzadoColorectal cancerAdvanced Colorectal CancerCáncer Colorectal AvanzadoColorectal CancerAdvanced Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2536604CanadaBelgiumUnited StatesSpain12ECRIN MDRCompletedfalsePhase II study of PM60184 in patients with advanced colon-rectal cancer after standard treatment.Primary objectives: To evaluate the efficacy of PM060184 in terms ofprogression-free survival at 12 weeks (PFS3) in patients withadvanced colorectal carcinoma (CRC) after standard therapy. Primary endpoints: PFS3, defined as the percentage of patients remaining aliveand progression-free at Week 12 (Month 3) after the firsttreatment dose.2017-12-1525366042017-000257-39